Lactobacillus rhamnosus synbiotics freeze-dried microcapsule as well as preparation method and application thereof

By preparing Lactobacillus rhamnosus lyophilized microcapsules, the problem of poor colonization ability of probiotics in the gastrointestinal tract is solved, the improvement of autism-related symptoms is achieved, and the product's resistance to gastric acid and intestinal fluid release ability is significantly improved. .

CN119074682APending Publication Date: 2024-12-06SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411211052.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing probiotic products have poor colonization ability in the gastrointestinal tract and cannot play a role effectively for a long time, resulting in less significant improvement of autism-related symptoms, mainly due to the effects of gastric acid, bile acid, extreme pH and microbial antagonism.

Method used

Lactobacillus rhamnosus synbiotic freeze-dried microcapsules, including Lactobacillus rhamnosus, prebiotics, pectin, glycerol, sodium L-ascorbate and skimmed milk powder, were prepared by vacuum freeze-drying technology to form gastric acid-resistant and intestinal fluid Release capacity microcapsules ensure that the active substance does not become inactive during environmental changes and is effectively delivered to the intestine.

Benefits of technology

It significantly improved the tolerance and stability of Lactobacillus rhamnosus in the gastrointestinal tract, achieved good intestinal colonization effect, and improved repetitive stereotyped behaviors and social ability disorders related to autism.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074682A_ABST
    Figure CN119074682A_ABST
Patent Text Reader

Abstract

The invention discloses lactobacillus rhamnosus as well as a synbiotic freeze-dried microcapsule, a preparation method and application thereof, and belongs to the technical field of synbiotic products. Lactobacillus rhamnosus, prebiotics, pectin, glycerol, L-sodium ascorbate and dried skim milk are used as raw materials to prepare the synbiotics freeze-dried microcapsule, and the synbiotics prepared by the method disclosed by the invention are used as a microecological preparation targeting intestinal tracts, and a good colonization effect is achieved after the synbiotics reach the intestinal tracts. The synbiotics are prepared into freeze-dried microcapsules, and a natural or artificially synthesized high-molecular compound is used as a wall material to wrap an active substance, so that the active substance lactobacillus rhamnosus overcomes environmental change without inactivation, and is delivered to a target position to play a role, thereby enhancing the endurance capacity of the lactobacillus rhamnosus in gastrointestinal tracts; the stability and the activity are greatly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of synbiotic products, and in particular to a Lactobacillus rhamnosus synbiotic freeze-dried microcapsule and a preparation method and application thereof. Background Art

[0002] Autism spectrum disorders (ASD), also known as autism, is a lifelong neurodevelopmental disorder characterized by defects in social communication and interaction, as well as limited and repetitive behavior or interest patterns. Currently, ASD has become an important public health issue affecting children's health. It not only greatly increases the economic burden on families, but also brings heavy economic pressure to society.

[0003] The exact pathogenesis of ASD is still unclear, and a large number of studies have shown that the interaction between genetic and environmental factors is the main influencing factor of ASD. People with specific genetic or chromosomal characteristics, such as Fragile X Syndrome (FXS), are more likely to suffer from autism. Environmental factors such as exposure to exogenous chemicals such as lipopolysaccharide and valproic acid (VPA) during pregnancy can directly affect the normal development of the fetal nervous system and increase the susceptibility to ASD. Gastrointestinal diseases are common in ASD patients, and gastrointestinal symptoms are correlated with the social status of ASD.

[0004] A large number of studies have shown that interventions such as prebiotics, probiotics, special diets, and fecal microbiota transplantation for improving intestinal flora can alleviate the symptoms of autism to a certain extent. CN112384081B discloses a group of nutritional compositions comprising human milk oligosaccharides, which have the effect of improving, enhancing, promoting or regulating the serotonergic function in the CNS in mammals, premature or full-term human infants or young children between birth and 7 years old. However, there is no function for improving autistic-like behaviors related to neurodevelopmental disorders. Lactobacillus rhamnosus has also been shown to improve anxiety and depression-related behaviors, but there is no application of Lactobacillus rhamnosus related products in intervening in neurodevelopmental disorders.

[0005] At present, the domestic and foreign markets mainly add single or multiple common probiotics and prebiotics products, and most probiotics have poor colonization ability after oral administration. As an important active substance, the vitality of probiotics will be affected by many factors during the colonization process. For example, gastric acid and bile acid secreted by the gastrointestinal tract, extreme pH, antimicrobial peptides, and antagonism between microorganisms all greatly inhibit the colonization of probiotics, resulting in the inability to effectively colonize in the intestine for a long time. Summary of the invention

[0006] The present invention provides a Lactobacillus rhamnosus synbiotic freeze-dried microcapsule and a preparation method and application thereof, which effectively solves the technical problem that the existing probiotics cannot be effectively colonized in the intestine for a long time due to the antagonism between gastric acid and bile acid secreted by the gastrointestinal tract, extreme pH, antimicrobial peptides and microorganisms, thereby weakening the improvement effect of probiotic products on ASD. At the same time, a synbiotic with the function of improving autistic-like behaviors of neurodevelopmental disorders is provided, and the prepared Lactobacillus rhamnosus synbiotic freeze-dried microcapsule has better gastric acid resistance and intestinal fluid release ability.

[0007] The first object of the present invention is to provide a Lactobacillus rhamnosus synbiotic freeze-dried microcapsule, characterized in that it comprises the following raw materials in mass percentage: 65% to 84% of Lactobacillus rhamnosus, 5% to 10% of prebiotics, 3% to 9% of pectin, 1% to 5% of glycerol, 1% to 5% of sodium L-ascorbate, and 6% to 14% of skim milk powder, which totals 100%; the viable count of the Lactobacillus rhamnosus is ≥ 1×10 10 CFU / g.

[0008] As a preferred embodiment, the Lactobacillus rhamnosus is Lactobacillus rhamnosus C502, which was deposited in Guangdong Provincial Microbiological Culture Collection Center on February 1, 2024, with a deposit number of GDMCC No. 64357.

[0009] As a preferred embodiment, the prebiotic is cereal β-glucan, including highland barley β-glucan or oat β-glucan.

[0010] The second object of the present invention is to provide a method for preparing the above-mentioned Lactobacillus rhamnosus synbiotic freeze-dried microcapsules, comprising the following steps:

[0011] Weigh the following raw materials in percentage by mass: 65% to 84% of Lactobacillus rhamnosus, 5% to 10% of prebiotics, 3% to 9% of pectin, 1% to 5% of glycerol, 1% to 5% of sodium L-ascorbate, and 6% to 14% of skim milk powder;

[0012] Dissolving prebiotics in water to form a prebiotic solution, inoculating Lactobacillus rhamnosus into MRS liquid culture medium, culturing at 37° C. for 24 to 48 hours, centrifuging to obtain bacterial sludge, and dissolving the bacterial sludge in the prebiotic solution to obtain a synbiotic mixed solution;

[0013] Dissolving pectin in water to form a pectin solution, adding the synbiotic mixture to the pectin solution, sterilizing, adding a sterile CaCl2 solution, and solidifying to obtain synbiotic microcapsules;

[0014] Glycerol, sodium L-ascorbate and skim milk powder are added to the synbiotic microcapsules, incubated, and vacuum freeze-dried to obtain Lactobacillus rhamnosus synbiotic freeze-dried microcapsules.

[0015] As a preferred embodiment, the prebiotic solution is a cereal β-glucan solution, and the concentration of the prebiotic solution is 50-100 g / L.

[0016] As a preferred embodiment, the mass concentration of the pectin solution is 1% to 3%, and the volume ratio of the pectin solution to the synbiotic mixture is 2 to 3:1.

[0017] As a preferred embodiment, the concentration of the sterile CaCl2 solution is 200-300 mmol / L, and the volume ratio of the synbiotic mixture to the sterile CaCl2 solution is 1:10-20.

[0018] As a preferred implementation, the curing time is 20 to 30 minutes.

[0019] As a preferred embodiment, the incubation time is 10 to 20 minutes.

[0020] As a preferred embodiment, the vacuum freeze-drying conditions are: pre-freezing at -80°C for 6 to 10 hours, freeze-drying temperature of -40 to -60°C, vacuum degree of 10 to 20 Pa, and freeze-drying time of 36 to 48 hours.

[0021] The third object of the present invention is to provide an application of Lactobacillus rhamnosus synbiotic freeze-dried microcapsules in the preparation of autistic-like behavior drugs for intervening in neurodevelopmental disorders, characterized in that the autistic-like behaviors of the neurodevelopmental disorders are repetitive stereotyped behaviors and / or social ability disorders.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention provides a Lactobacillus rhamnosus synbiotic freeze-dried microcapsule and a preparation method and application thereof. The synbiotic freeze-dried microcapsule is prepared from Lactobacillus rhamnosus, prebiotics, pectin, glycerol, sodium L-ascorbate, and skim milk powder as raw materials. The synbiotic prepared by the present invention is a microecological preparation targeting the intestinal tract, and achieves a good colonization effect after reaching the intestinal tract. The synbiotic is prepared as a freeze-dried microcapsule, and the active substance is wrapped using a natural or synthetic polymer compound as a wall material, so that the active substance Lactobacillus rhamnosus overcomes environmental changes without inactivation, and is delivered to the target position to play a role, thereby enhancing the tolerance of Lactobacillus rhamnosus in the gastrointestinal tract and greatly improving its stability and activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Synbiotics improve autistic-like behaviors in mice with environmentally induced neurodevelopmental disorders, where A is the self-grooming test, B is the social preference index, and C is the social novelty index;

[0025] Figure 2 Synbiotics improve autistic-like behaviors in gene mutation-type neurodevelopmental disorder model mice, where A is the self-grooming test, B is the social preference index, and C is the social novelty index;

[0026] Figure 3 The effects of different concentrations of single lyophilization protective agents on the embedding rate of probiotics in lyophilized microcapsules, among which Figure A is sodium L-ascorbate, Figure B is skim milk powder, and Figure C is glycerol;

[0027] Figure 4 The in vitro digestion stability evaluation of the freeze-dried microcapsules of Lactobacillus rhamnosus synbiotics is shown in Figure A, where Figure B shows the survival rate of the freeze-dried microcapsules of synbiotics in artificial gastric juice, and Figure A shows the release rate of the freeze-dried microcapsules of synbiotics in artificial intestinal juice.

[0028] Figure 5 These are display pictures of Lactobacillus rhamnosus synbiotic freeze-dried microcapsules, among which Picture A is a real picture of synbiotic microcapsules, Picture B is a real picture of synbiotic freeze-dried microcapsules, Picture C is an enlarged picture of synbiotic microcapsules, and Picture D is an enlarged picture of synbiotic freeze-dried microcapsules.

[0029] Figure 6 It is a growth curve diagram of Lactobacillus rhamnosus C502 of the present invention and different types of prebiotics. DETAILED DESCRIPTION

[0030] In order to enable those skilled in the art to better understand the technical solution of the present invention and implement it, the present invention is further described below in conjunction with specific examples, but the examples are not intended to limit the present invention. The following test methods and detection methods, unless otherwise specified, are conventional methods; the reagents and raw materials, unless otherwise specified, are commercially available.

[0031] In view of the existing products mentioned in the background technology of the present invention that add single or multiple common probiotics and prebiotics, most probiotics have poor colonization ability after oral administration. As an important active substance, the vitality of probiotics will be affected by many factors during the colonization process, such as gastric acid and bile acid secreted by the gastrointestinal tract, extreme pH, antimicrobial peptides, and antagonism between microorganisms, which greatly inhibit the colonization of probiotics, resulting in the inability of probiotics to effectively play a role in the intestine for a long time, so the improvement effect of probiotics on autism is not significant. Based on the above technical problems, the present invention provides a Lactobacillus rhamnosus synbiotic freeze-dried microcapsule and its preparation method and application.

[0032] The technical solution of the present invention is described in detail below.

[0033] The present invention first provides a Lactobacillus rhamnosus synbiotic freeze-dried microcapsule, comprising the following raw materials in mass percentage: 65% to 84% of Lactobacillus rhamnosus, 5% to 10% of prebiotics, 3% to 9% of pectin, 1% to 5% of glycerol, 1% to 5% of L-sodium ascorbate, and 6% to 14% of skim milk powder, which totals 100%. The Lactobacillus rhamnosus is Lactobacillus rhamnosus C502, with a preservation number of GDMCC No. 64357. The number of viable bacteria of the Lactobacillus rhamnosus per gram of the Lactobacillus rhamnosus synbiotic freeze-dried microcapsule is ≥ 1×10 10 CFU / g.

[0034] In the above technical scheme, synbiotic freeze-dried microcapsules are prepared with Lactobacillus rhamnosus, prebiotics, pectin, glycerol, sodium L-ascorbate and skimmed milk powder as raw materials. The synbiotic prepared by the present invention is a microecological preparation targeting the intestine, which achieves a good colonization effect after reaching the intestine. The synbiotic is prepared into freeze-dried microcapsules, and the active substance is wrapped with natural or synthetic polymer compounds as wall materials, so that the active substance Lactobacillus rhamnosus overcomes environmental changes without inactivation and is delivered to the target position to exert its effect, thereby enhancing the tolerance of Lactobacillus rhamnosus in the gastrointestinal tract and greatly improving its stability and activity.

[0035] The number of viable bacteria is one of the important indicators to measure the effect of the synbiotic. Insufficient viable bacteria means that the number of effective probiotics per gram of the product is reduced, and more inactive ingredients or impurities are mixed into the product, which will directly affect its colonization ability in the intestine and its regulatory effect on the intestinal flora. Lactobacillus rhamnosus C502 can inhibit the growth of harmful bacteria and promote the reproduction of beneficial bacteria in the intestine, thereby improving intestinal health. However, if the number of viable bacteria is insufficient, its ability to inhibit harmful bacteria and promote the growth of beneficial bacteria will be limited, which may lead to a lack of obvious effect on improving intestinal health. Therefore, the effect of probiotics may be greatly reduced and the expected health benefits cannot be achieved.

[0036] For the above raw materials, Lactobacillus rhamnosus and prebiotics constitute synbiotics. Pectin, as a natural plant polysaccharide, has good film-forming properties and viscosity, and is an important component of the microcapsule wall material. The right amount of pectin can ensure the stability and integrity of the microcapsule wall material, thereby effectively protecting the activity of probiotics during storage and transportation. Too low a pectin content may not form a sufficient wall material layer, resulting in a weakened protective effect of the microcapsule; while too high a pectin content may increase the difficulty and cost of preparing the microcapsule, and may also affect the taste and solubility of the product. Therefore, the mass percentage of pectin is selected to be 3% to 9%.

[0037] Glycerin is mainly used as a humectant and plasticizer in microcapsules, which can improve the flexibility and elasticity of the wall material and reduce the cracking and breakage of the microcapsules during the drying process. The dosage of glycerin ranges from 1% to 5%. This choice may be to ensure the flexibility of the microcapsule wall material while avoiding excessive viscosity and hygroscopicity caused by adding too much glycerin, which in turn affects the storage stability and use effect of the product.

[0038] As an antioxidant, sodium ascorbate can effectively remove free radicals and prevent probiotics from oxidative damage during storage and transportation. The dosage range of sodium L-ascorbate is between 1% and 5%, and this range may be selected based on the effectiveness and economic considerations of its antioxidant capacity. An appropriate amount of sodium L-ascorbate can ensure the stability of probiotics during storage, while too high a dosage may increase costs and may not necessarily bring additional antioxidant effects.

[0039] Skim milk powder is an important nutrient source and protective agent in microcapsules. It is rich in nutrients and can provide necessary growth factors and nutrients for probiotics. At the same time, components such as protein and lactose in skim milk powder can also interact with the hydrophilic groups on the surface of probiotics to form a stable protective layer. The dosage range of skim milk powder is between 6% and 14%. The selection of this range may be the result of comprehensive consideration based on the growth requirements of probiotics and the taste and solubility of the product. The right amount of skim milk powder can ensure that the nutritional needs of probiotics are met during storage while maintaining the good taste and solubility of the product.

[0040] It should be noted that the prebiotic is a cereal β-glucan, including highland barley β-glucan or oat β-glucan. In the early stage of the study, the growth curve of Lactobacillus rhamnosus C502 and other types of prebiotics was made, and it was found that the strain had the highest efficiency in utilizing β-glucan from cereal sources (highland barley, oats). Figure 6 After further sequencing of the strain and annotation of its CAZy enzyme, it was found that the strain has glycosidic bond hydrolases for cereal β-glucans, such as the exo-β-1.4-glucanase GH1 family.

[0041] The second object of the present invention is to provide a method for preparing the above-mentioned Lactobacillus rhamnosus synbiotic freeze-dried microcapsules, comprising the following steps:

[0042] Weigh the following raw materials in percentage by mass: 65% to 84% of Lactobacillus rhamnosus, 5% to 10% of prebiotics, 3% to 9% of pectin, 1% to 5% of glycerol, 1% to 5% of sodium L-ascorbate, and 6% to 14% of skim milk powder;

[0043] Dissolving prebiotics in water to form a prebiotic solution, inoculating Lactobacillus rhamnosus into MRS liquid culture medium, culturing at 37° C. for 24 to 48 hours, centrifuging to obtain bacterial sludge, and dissolving the bacterial sludge in the prebiotic solution to obtain a synbiotic mixed solution;

[0044] Dissolving pectin in water to form a pectin solution, adding the synbiotic mixture to the pectin solution, sterilizing, adding a sterile CaCl2 solution, and solidifying to obtain synbiotic microcapsules;

[0045] Glycerol, sodium L-ascorbate and skim milk powder are added to the synbiotic microcapsules, incubated, and vacuum freeze-dried to obtain Lactobacillus rhamnosus synbiotic freeze-dried microcapsules.

[0046] In order to further achieve a good proliferation effect of Lactobacillus rhamnosus, the prebiotic solution uses a cereal β-glucan solution. Lactobacillus rhamnosus C502 has the highest utilization efficiency of β-glucan from cereal sources (highland barley, oats).

[0047] In order to ensure the storage stability and use effect of the Lactobacillus rhamnosus synbiotic freeze-dried microcapsules, the mass concentration of the pectin solution is 1% to 3%, and the volume ratio of the pectin solution to the synbiotic mixture is 2 to 3:1.

[0048] It should be noted that the concentration of the sterile CaCl2 solution is 200-300 mmol / L, and the volume ratio of the synbiotic mixture to the sterile CaCl2 solution is 1:10-20.

[0049] CaCl2 plays a role in cross-linking and curing in the preparation of microcapsules. When wall materials such as pectin come into contact with CaCl2 solution, the carboxyl groups in the pectin molecules will cross-link with CaCl2. 2+ The ions undergo cross-linking reaction to form a stable gel network structure, thereby embedding core substances such as probiotics and prebiotics. The concentration range of 200-300mmol / L is obtained after experimental optimization. This concentration range can ensure that the pectin molecules are fully cross-linked to form a stable microcapsule wall material with a certain mechanical strength, while not causing excessive cross-linking due to excessive concentration, which affects the flexibility and release performance of the microcapsule.

[0050] In order to ensure the curing effect, the curing time is 20 to 30 minutes.

[0051] The curing time refers to the time required for the cross-linking reaction to occur after the pectin contacts the CaCl2 solution. During this period of time, the cross-linking reaction gradually proceeds until a stable gel network structure is formed. The curing time of 20 to 30 minutes is based on experimental observations and result analysis. During this period of time, the cross-linking reaction can be fully carried out, while avoiding the possibility that the microcapsule structure may be too dense due to too long a curing time, which may affect the release and activity of probiotics.

[0052] The incubation time is 10 to 20 minutes. The incubation time of 10 to 20 minutes ensures that additives such as glycerol, sodium L-ascorbate and skim milk powder can fully penetrate into the microcapsule wall material and play their respective roles. At the same time, this time period also avoids the microcapsule structure change or performance degradation that may be caused by too long an incubation time.

[0053] It should be emphasized that the vacuum freeze-drying conditions are: pre-freezing at -80°C for 6 to 10 hours, freeze-drying temperature of -40 to -60°C, vacuum degree of 10 to 20 Pa, and freeze-drying time of 36 to 48 hours.

[0054] The vacuum freeze drying condition of -80℃ pre-freezing for 6 to 10 hours is to ensure that the food is quickly and completely frozen at low temperature, thereby forming small and uniform ice crystals. This low-temperature pre-freezing not only inhibits the activity of microorganisms, but also lays the foundation for the subsequent sublimation drying process. The freeze drying temperature is set at -40 to -60℃: the low temperature environment causes the ice crystals to sublimate directly into water vapor, avoiding the damage to food quality caused by the thawing and refreezing process in the traditional drying method. The vacuum degree is maintained at 10 to 20Pa: the low vacuum environment promotes the rapid diffusion of water vapor, further improving the drying efficiency. The drying time of 36 to 48 hours is based on a comprehensive consideration of the type, size and required degree of drying of the food, aiming to achieve a balance of heat and mass transfer, ensuring that the microcapsules can fully remove moisture and maintain their original nutrients during the drying process.

[0055] The technical effects of the present invention are described below in conjunction with specific embodiments and comparative examples. The Lactobacillus rhamnosus C502 described in the present invention was deposited in the Guangdong Provincial Microbiological Culture Collection Center on February 1, 2024, and the preservation classification was named: Lacticaseibacillus rhamnosus, and the preservation number was GDMCC No.64357.

[0056] Example 1

[0057] A Lactobacillus rhamnosus synbiotic freeze-dried microcapsule is prepared from the following raw materials in percentage by mass: 70% of Lactobacillus rhamnosus C502, 8% of highland barley β-glucan, 6% of pectin, 4% of glycerol, 4% of sodium L-ascorbate, and 8% of skim milk powder, which totals 100%; the viable cell count of the Lactobacillus rhamnosus C502 is ≥1×10 10 CFU / g.

[0058] The rhamnosus Lactobacillus C502 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on February 1, 2024, with the collection number GDMCC No.64357.

[0059] The preparation method of the above-mentioned Lactobacillus rhamnosus synbiotic freeze-dried microcapsules comprises the following steps:

[0060] Weigh the raw materials according to the above mass percentages: Lactobacillus rhamnosus C502 70%, highland barley β-glucan 8%, pectin 6%, glycerol 4%, sodium L-ascorbate 4%, skim milk powder 8%;

[0061] Dissolving highland barley β-glucan in water to obtain a highland barley β-glucan solution (prebiotic solution) with a concentration of 80 g / L, inoculating Lactobacillus rhamnosus C502 into an MRS liquid culture medium, culturing at 37° C. for 30 hours, centrifuging to obtain bacterial sludge, and dissolving the bacterial sludge in a highland barley β-glucan solution with a concentration of 80 g / L to obtain a synbiotic mixed solution;

[0062] Dissolve pectin in water to obtain a pectin solution with a concentration of 2%, add the synbiotic mixture to the pectin solution with a mass concentration of 2% at a volume ratio of 1:2, sterilize, add a sterile CaCl2 solution with a concentration of 200 mmol / L at a volume ratio of 1:10 between the synbiotic mixture and the sterile CaCl2 solution, and solidify for 20 minutes to obtain synbiotic microcapsules;

[0063] Glycerol, sodium L-ascorbate and skim milk powder were added to the synbiotic microcapsules, incubated for 10 minutes, pre-frozen at -80°C for 6 hours, and freeze-dried at -50°C and a vacuum degree of 20 Pa for 36 hours to obtain Lactobacillus rhamnosus synbiotic freeze-dried microcapsules.

[0064] Example 2

[0065] A Lactobacillus rhamnosus synbiotic freeze-dried microcapsule is prepared from the following raw materials in percentage by mass: 65% of Lactobacillus rhamnosus C502, 10% of oat beta-glucan, 6% of pectin, 5% of glycerol, 4% of sodium L-ascorbate, and 10% of skim milk powder, which totals 100%; the viable count of the Lactobacillus rhamnosus C502 is ≥1×10 10 CFU / g.

[0066] The rhamnosus Lactobacillus C502 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on February 1, 2024, with the collection number GDMCC No.64357.

[0067] The preparation method of the above-mentioned Lactobacillus rhamnosus synbiotic freeze-dried microcapsules comprises the following steps:

[0068] Weigh the raw materials according to the above mass percentages: Lactobacillus rhamnosus C50265%, oat beta-glucan 10%, pectin 6%, glycerol 5%, sodium L-ascorbate 4%, skim milk powder 10%;

[0069] Dissolving highland barley β-glucan in water to obtain an oat β-glucan solution (prebiotic solution) with a concentration of 100 g / L, inoculating Lactobacillus rhamnosus C502 into an MRS liquid culture medium, culturing at 37° C. for 24 hours, centrifuging to obtain bacterial sludge, and dissolving the bacterial sludge in an oat β-glucan solution with a concentration of 100 g / L to obtain a synbiotic mixture;

[0070] Dissolve pectin in water to obtain a pectin solution with a concentration of 1%, add the synbiotic mixture to the pectin solution with a mass concentration of 1% at a volume ratio of 1:3, sterilize, add a sterile CaCl2 solution with a concentration of 300 mmol / L at a volume ratio of 1:20 between the synbiotic mixture and the sterile CaCl2 solution, and solidify for 30 minutes to obtain synbiotic microcapsules;

[0071] Glycerol, sodium L-ascorbate and skim milk powder were added to the synbiotic microcapsules, incubated for 20 minutes, pre-frozen at -80°C for 10 hours, and freeze-dried at -60°C and a vacuum degree of 20 Pa for 48 hours to obtain Lactobacillus rhamnosus synbiotic freeze-dried microcapsules.

[0072] Example 3

[0073] A Lactobacillus rhamnosus synbiotic freeze-dried microcapsule is prepared from the following raw materials in percentage by mass: 84% of Lactobacillus rhamnosus C502, 5% of highland barley β-glucan, 3% of pectin, 1% of glycerol, 1% of sodium L-ascorbate, and 6% of skim milk powder, which totals 100%; the viable cell count of the Lactobacillus rhamnosus C502 is ≥1×10 10 CFU / g.

[0074] The rhamnosus Lactobacillus C502 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on February 1, 2024, with the collection number GDMCC No.64357.

[0075] The preparation method of the above-mentioned Lactobacillus rhamnosus synbiotic freeze-dried microcapsules comprises the following steps:

[0076] Weigh the raw materials according to the above mass percentages: Lactobacillus rhamnosus C50284%, highland barley β-glucan 5%, pectin 3%, glycerol 1%, sodium L-ascorbate 1%, and skim milk powder 6%;

[0077] Dissolving highland barley β-glucan in water to obtain a highland barley β-glucan solution (prebiotic solution) with a concentration of 50 g / L, inoculating Lactobacillus rhamnosus C502 into an MRS liquid culture medium, culturing at 37° C. for 48 hours, centrifuging to obtain bacterial sludge, and dissolving the bacterial sludge in a highland barley β-glucan solution with a concentration of 50 g / L to obtain a synbiotic mixed solution;

[0078] Dissolve pectin in water to obtain a pectin solution with a concentration of 3%, add the synbiotic mixture to the pectin solution with a mass concentration of 3% at a volume ratio of 1:2.4, sterilize, add a sterile CaCl2 solution with a concentration of 260 mmol / L at a volume ratio of 1:15 between the synbiotic mixture and the sterile CaCl2 solution, and solidify for 25 minutes to obtain synbiotic microcapsules;

[0079] Glycerol, sodium L-ascorbate and skim milk powder were added to the synbiotic microcapsules, incubated for 16 minutes, pre-frozen at -80°C for 8 hours, and freeze-dried at -40°C and a vacuum degree of 16 Pa for 40 hours to obtain Lactobacillus rhamnosus synbiotic freeze-dried microcapsules.

[0080] The performance of the lyophilized microcapsules of the synbiotics prepared in Examples 1 to 3 was tested, and the results are as follows:

[0081] Experimental Example 1: Experiment on improving autistic behavior in environment-induced ASD model mice

[0082] The efficacy of the synbiotic freeze-dried microcapsules of the present invention was evaluated by animal experiments to illustrate the effectiveness of the synbiotics.

[0083] 1. Grouping and treatment of experimental animals

[0084] Construction of environmentally induced ASD mice: The ASD model of male offspring mice was established by intraperitoneal injection of valproic acid (VPA) on day 12.5 of the maternal gestation, and the control group (CON) model of male offspring mice was established by intraperitoneal injection of normal saline on day 12.5 of the maternal gestation. Three-week-old ASD model mice and CON model mice were selected and divided into three groups: control group (CON), model group (VPA), and model supplemented synbiotic group (VPA+S), with 10 mice in each group, and each group was from at least three different maternal generations. The mice in the VPA+S group were given synbiotics (Lactobacillus rhamnosus C502 (1.0×10 9 The mice in the CON and VPA groups were given oral gavage with the same volume of normal saline for 4 weeks.

[0085] 2. Sample collection and analysis test

[0086] After the mice were fed for 4 weeks, the behavior of the offspring mice was evaluated at 7-8 weeks of age.

[0087] 3. Experimental Methods

[0088] Three-chamber socialization: used to measure the sociability and social novelty of mice. A 60×40cm 2The plexiglass box was divided into three chambers, the left, middle, and right. The time the mouse entered each chamber was recorded in the first 10 minutes; in the second 10 minutes, an empty wire cup (empty cup) was placed in the middle of the left chamber, and a wire cup containing an age- and sex-matched stranger mouse (mouse 1) was placed in the middle of the right chamber. The time the tested mouse interacted with the empty cup and the time it interacted with the stranger mouse was recorded; in the third 10 minutes, a new stranger mouse was placed in the empty cup in the left chamber (mouse 2), and the time the tested mouse interacted with the two mice on the left and right was also recorded. Before each mouse was tested, it was wiped clean with 75% alcohol to remove odor. The social preference index was calculated as: (time interacting with mouse 1-time interacting with the empty cup) / (time interacting with mouse 1+time interacting with the empty cup). The social novelty index was calculated as (time interacting with mouse 2-time interacting with mouse 1) / (time interacting with mouse 2+time interacting with mouse 1).

[0089] Self-grooming: used to evaluate the repetitive behavior of mice. In order to adapt to the environment, the mice were placed individually in a clean cage of 25cm×18cm×16cm. After 10 minutes of free activity, the time of licking paws, grooming the body or scratching of the mice in the second 10 minutes was recorded. Before testing each mouse, the experimental apparatus was wiped with 75% alcohol.

[0090] Experimental Results

[0091] The effect of synbiotics on repetitive stereotypic behaviors of environmentally induced ASD mice was evaluated by self-grooming test. Compared with the control group, synbiotic treatment significantly reduced the grooming time of ASD mice in the self-grooming test. Figure 1 Figure A. The social ability of mice was evaluated using the three-chamber social test. Figure 1 As shown in Figures B and C, the social preference index and social novelty index of ASD model mice after synbiotic intervention were significantly increased compared with those of control mice. This indicates that synbiotic intervention can improve the social deficits of ASD mice. The above results indicate that synbiotics can significantly improve the repetitive behaviors and social deficits of ASD mice.

[0092] Experimental Example 2: Experiment on improving autistic behavior in gene mutation ASD model mice

[0093] 1. Grouping and treatment of experimental animals

[0094] 3-week-old male Fmr1 - / y Twenty mice and WT mice were divided into three groups: control group (CON), model group (FXS), and model supplemented with synbiotics group (FXS+S), with 10 mice in each group. The mice were given synbiotics or an equal volume of saline for 4 weeks.

[0095] 2. Sample collection, analysis, testing and experimental methods are the same as those in Experiment 1.

[0096] Experimental Results

[0097] Compared with the control group, Fmr1 - / y Mice had significant stereotyped behaviors and social impairment. After 4 weeks of continuous intervention with synbiotics, Fmr1 - / y The mice's self-grooming time was significantly reduced. Figure 2 Figure A in Figure 1 shows the social preference index. Figure 2 Figure B in Figure 2 shows that the social novelty index has increased significantly. Figure 2 Figure C. The above results indicate that synbiotics can significantly improve the repetitive behaviors and social deficits of gene-deficient ASD mice.

[0098] Experimental Example 3: Effects of Sodium L-ascorbate, Skim Milk Powder and Glycerol on the Embedding Efficiency of Biostime Freeze-dried Microcapsules

[0099] 1. The preparation of synbiotic suspension is the same as that of Experimental Examples 1 and 2.

[0100] 2. Preparation of synbiotic microcapsules: Prepare 2% (w / v) pectin solution, place in a clean bench for 30 minutes in a water bath at 90°C to kill microorganisms. Then add pectin solution to the synbiotic suspension at a ratio of synbiotic suspension: pectin solution = 1:3, mix well, and then use a 1mL sterile syringe to slowly drip the solution into a 300mmoL / L sterile CaCl2 solution to form synbiotic microcapsules.

[0101] 3. The synbiotic microcapsules were rinsed three times with sterile PBS to wash away the residual CaCl2 solution, and then the microcapsules were placed in a sterile culture dish, and 1%, 2%, 3%, 4%, and 5% of L-sodium ascorbate were added, respectively. The microcapsules were pre-frozen at -80°C for 6 hours, and then placed in a vacuum freeze dryer (-50°C, 20pa) for 36 hours of freeze drying to obtain synbiotic freeze-dried microcapsules 1 with the protective agent being L-sodium ascorbate.

[0102] 4. The synbiotic microcapsules were rinsed three times with sterile PBS to wash away the residual CaCl2 solution, and then the microcapsules were placed in a sterile culture dish, and 6%, 8%, 10%, 12%, and 14% skim milk powder were added respectively, and pre-frozen at -80°C for 6 hours, and then placed in a vacuum freeze dryer (-50°C, 20pa) for 36 hours of freeze drying to obtain synbiotic freeze-dried microcapsules 2 with skim milk powder as the protective agent.

[0103] 5. The synbiotic microcapsules were rinsed three times with sterile PBS to wash away the residual CaCl2 solution, and then the microcapsules were placed in a sterile culture dish, and 1%, 2%, 3%, 4%, and 5% glycerol were added respectively, and pre-frozen at -80°C for 6 hours, and then placed in a vacuum freeze dryer (-50°C, 20pa) for 36 hours of freeze drying to obtain synbiotic freeze-dried microcapsules 3 with glycerol as the protective agent.

[0104] 6. Determination of embedding rate: Take 1mL of synbiotic suspension and dilute it with sterile PBS and count it on the plate to calculate the total number of bacteria in the suspension. Add 1mL of synbiotic suspension to 40mL of sterile 0.06moL / L sodium citrate solution, bathe it in 37℃ for 1h to release the bacteria, then dilute it with sterile PBS and count it on the plate to obtain the total number of colonies in the freeze-dried microcapsules. Finally, calculate the embedding rate based on the ratio of the total number of colonies in the freeze-dried microcapsules to the total number of colonies in the suspension.

[0105] Experimental Results

[0106] Depend on Figure 3 It can be seen that the freeze-drying protection effects of the three freeze-drying protective agents, L-ascorbate sodium, skim milk powder, and glycerol, on the synbiotic microcapsules showed a trend of first increasing and then decreasing. Among them, the protection effect of L-ascorbate sodium on the microcapsules was the best when the addition amount was 4%. Figure 3 In Figure A, skim milk powder has the strongest protective effect at a 10% addition level. Figure 3 In Figure B, the embedding efficiency of glycerol reaches the maximum at a concentration of 3%. Figure 3 Figure C. Therefore, it can be preliminarily confirmed that the optimal concentrations of the three lyophilization protectants are: L-ascorbic acid sodium-4%, skim milk powder-10%, and glycerol-3%.

[0107] Test Example 4

[0108] Effects of sodium L-ascorbate, skim milk powder, and glycerol composite protective agent on lyophilized microcapsules of synbiotics:

[0109] 1. The preparation of the synbiotic mixture is the same as that of Experimental Examples 1 and 2.

[0110] 2. The preparation of synbiotic microcapsules is the same as that of Experimental Examples 1 and 2.

[0111] 3. The effects of different protective agents on the embedding efficiency of synbiotics freeze-dried microcapsules are the same as in Experiment 3.

[0112] 4. The optimal ratio of composite protective agent was screened out by designing orthogonal experiments. The orthogonal factor levels are: L-sodium ascorbate: 3%, 4%, 5%; skim milk powder: 8%, 10%, 12%; glycerol: 2%, 3%, 4%. The embedding rate was used as the evaluation index, and the results are shown in Table 1:

[0113] Table 1 Effect of synergistic effects of various protective agents on the embedding rate of probiotics in freeze-dried microcapsules

[0114]

[0115] Through orthogonal experimental data, it can be concluded that among the three protective agents, sodium L-ascorbate, skim milk powder and glycerol, sodium L-ascorbate has the greatest impact, followed by glycerol, and skim milk powder has the least impact. From the perspective of single average values, the optimal level of glycerol is 4%, the optimal level of sodium L-ascorbate is 4%, and the optimal level of skim milk powder is 8%. That is, the optimal composite freeze-drying protective agent ratio of Biostime microcapsules is 4% glycerol, 4% sodium L-ascorbate and 8% skim milk powder. Under this condition, the encapsulation rate of the microcapsules reached 93.13%.

[0116] Test Example 5 Evaluation of the properties of lyophilized microcapsules of Biostime

[0117] 1. Acid resistance test of Biostime freeze-dried microcapsules

[0118] The synbiotic bacterial solution was added at 1% of artificial gastric juice, and microcapsules and freeze-dried microcapsules were added at 5%. The constant temperature shaker (37°C, 60 rpm) was started to simulate the digestion state. Samples were taken at 0 min, 30 min, 60 min, 90 min, and 120 min to detect the number of live bacteria.

[0119] 2. Enteric Solubility Test of Biostime Freeze-dried Microcapsules

[0120] Preparation of artificial intestinal fluid: Weigh 0.3g of pig bile salt, dissolve in 100mL sterile water, add trypsin at an addition amount of 10g / L, and then filter and sterilize with a 0.22μm filter membrane. Add synbiotic bacterial solution, synbiotic microcapsules and synbiotic freeze-dried microcapsules at an addition amount of 1% of artificial intestinal fluid, start a constant temperature shaker (37°C, 60 rpm) to simulate the digestion state, and take samples at 0 minutes, 15 minutes, 30 minutes, 45 minutes, and 60 minutes to detect the number of viable bacteria.

[0121] Experimental Results

[0122] The acid resistance of microcapsules Figure 4 As shown in Figure A, it can be seen that with the increase of digestion time, the survival rate of the synbiotic suspension in artificial gastric juice decreased significantly, indicating that the probiotics were digested, and the encapsulation of synbiotics can increase the survival rate of probiotics. Compared with the non-freeze-dried microcapsule group, the freeze-dried microcapsules showed better protection for probiotics. Figure 4As shown in Figure B, it can be seen that artificial intestinal fluid has no significant effect on the activity of probiotics. The microcapsules will gradually unzip and release the embedded probiotics in the artificial intestinal fluid. Compared with the non-freeze-dried microcapsules, the freeze-dried microcapsules unzip faster in the artificial intestinal fluid. Figure 5 , we can see that the surface of the microcapsules before freeze-drying is uniform and has good encapsulation ability for the wall core, e.g. Figure 5 In Figures A and C, the microcapsules shrink after freeze-drying, but the effect on the wall core is small. Figure 5 The above results show that the lyophilized microcapsules of Biostime have better gastric acid resistance and intestinal fluid release ability.

[0123] In summary, the synbiotic prepared by the present invention, as a microecological preparation targeting the intestine, achieves a good colonization effect after reaching the intestine. The synbiotic is prepared as a freeze-dried microcapsule, and the active substance is wrapped with a natural or synthetic polymer compound as a wall material, so that the active substance Lactobacillus rhamnosus overcomes environmental changes without inactivation, and is delivered to the target location to exert its effect, thereby enhancing the tolerance of Lactobacillus rhamnosus in the gastrointestinal tract and greatly improving its stability and activity.

[0124] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A Lactobacillus rhamnosus synbiotic freeze-dried microcapsule, It is characterized in that The invention comprises the following raw materials in percentage by weight: 65% to 84% of Lactobacillus rhamnosus, 5% to 10% of prebiotics, 3% to 9% of pectin, 1% to 5% of glycerol, 1% to 5% of L-sodium ascorbate, and 6% to 14% of skim milk powder, which totals 100%; and the number of viable Lactobacillus rhamnosus per gram of the lyophilized microcapsules is ≥ 1×10 10 CFU / g.

2. The Lactobacillus rhamnosus synbiotic freeze-dried microcapsule according to claim 1, It is characterized in that The rhamnosus Lactobacillus is rhamnosus Lactobacillus C502, which was deposited in Guangdong Provincial Microbiological Culture Collection Center on February 1, 2024, with the deposit number GDMCC No.64357.

3. The Lactobacillus rhamnosus synbiotic freeze-dried microcapsules according to claim 1, It is characterized in that The prebiotic is cereal β-glucan.

4. A method for preparing the Lactobacillus rhamnosus synbiotic freeze-dried microcapsules according to any one of claims 1 to 3, It is characterized in that The following steps are involved: Weigh the following raw materials in percentage by mass: 65% to 84% of Lactobacillus rhamnosus, 5% to 10% of prebiotics, 3% to 9% of pectin, 1% to 5% of glycerol, 1% to 5% of sodium L-ascorbate, and 6% to 14% of skim milk powder; Dissolving prebiotics in water to form a prebiotic solution, inoculating Lactobacillus rhamnosus into MRS liquid culture medium, culturing at 37° C. for 24 to 48 hours, centrifuging to obtain bacterial sludge, and dissolving the bacterial sludge in the prebiotic solution to obtain a synbiotic mixed solution; Pectin is dissolved in water to form a pectin solution, the synbiotic mixture is added to the pectin solution, sterilized, and sterile CaCl is added 2 solution, solidified, and obtained synbiotic microcapsules; Glycerol, sodium L-ascorbate and skim milk powder are added to the synbiotic microcapsules, incubated, and vacuum freeze-dried to obtain Lactobacillus rhamnosus synbiotic freeze-dried microcapsules.

5. The preparation method according to claim 4, It is characterized in that The prebiotic solution is a cereal beta-glucan solution, and the concentration of the prebiotic solution is 50-100 g / L.

6. The preparation method according to claim 4, It is characterized in that The mass concentration of the pectin solution is 1% to 3%, and the volume ratio of the pectin solution to the synbiotic mixture is 2 to 3:

1.

7. The preparation method according to claim 4, It is characterized in that The sterile CaCl 2 The concentration of the solution is 200-300 mmol / L. The synbiotic mixture is mixed with sterile CaCl 2 The volume ratio of the solution is 1:10-20.

8. The preparation method according to claim 4, It is characterized in that The solidification time is 20 to 30 minutes, and the incubation time is 10 to 20 minutes.

9. The preparation method according to claim 4, It is characterized in that The vacuum freeze drying conditions are: pre-freezing at -80°C for 6 to 10 hours, freeze drying temperature at -40 to -60°C, vacuum degree at 10 to 20 Pa, and freeze drying time at 36 to 48 hours.

10. Use of the Lactobacillus rhamnosus synbiotic freeze-dried microcapsules according to claim 1 in the preparation of autistic behavior drugs for intervention in neurodevelopmental disorders, It is characterized in that The autistic-like behaviors of the neurodevelopmental disorder are repetitive stereotyped behaviors and / or social ability disorders.